Summary
According to a post on X by @ScienceCorp_, the company's chief medical officer for ophthalmology summarized PRIMA presentations at the American Academy of Ophthalmology meeting. The presentations included 36-month results from the pivotal PRIMAvera trial, which studied people with geographic atrophy from age-related macular degeneration. The company's write-up of that follow-up says 38 people were implanted at 17 European sites and that 27 participants were evaluated at 36 months. The excerpt cuts off before the rest of that finding.
AI-assisted summary based on the listed source.
What happened
Science Corporation said its chief medical officer for ophthalmology summarized PRIMA presentations at the American Academy of Ophthalmology meeting, including 36-month results from the pivotal PRIMAvera trial in people with geographic atrophy from age-related macular degeneration. The company’s write-up of that...
Why it matters
Clinicians, patients with geographic atrophy, and investors following this technology would be most interested in longer-term follow-up data from the trial. The available excerpt does not include the full outcome figures, so the complete results would need to come from the company's full write-up or the presentations. The next thing to watch is how the 36-month findings are reported in those complete materials.
Signal Intelligence
Signal Strength 78%
Technical label WATCH
Public Interest 20
Category DEVELOPING
Reader Depth TECHNICAL
Signal Strength reflects source quality, relevance, freshness and evidence. Public Interest helps organize discovery; it is not proof of truth.
Public Interest components
Recognizable Entity Score 0
Practical Impact Score 0
Novelty Interest Score 70
Consequence Score 10
Curiosity Score 0
Shareability Score 41
Why this is here
VQV surfaced this signal because it is recent, relevant to AI Search, connected to Scobleizer News Pulse (X).
